Drug Profile
Research programme: melanocortin-4 receptor agonists - Merck
Alternative Names: MB 243; RY 764Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Erectile dysfunction
- Discontinued Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA (PO)
- 09 Sep 2009 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 28 Feb 2006 A preclinical study has been added to the pharmacokinetics and Obesity pharmacodynamics sections